Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,254

Document Document Title
WO/2019/014300A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2019/014303A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/011167A1
The invention relates to the field of biological medicines, in particular to a bispecific recombinant protein, a nucleic acid molecule for encoding the bispecific recombinant protein, a preparation method thereof, the use of the recombin...  
WO/2019/014308A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2019/007991A1
The present disclosure relates to a MTMR2-S polypeptide, or a nucleic acid sequence producing or encoding said MTMR2-S polypeptide, for a use in the treatment of a disease or disorder associated with MTM1 mutation or deficiency. The pres...  
WO/2019/006690A1
Provided are a polypeptide pharmaceutically acceptable salt and a pharmaceutical composition thereof, said polypeptide containing an amino acid sequence YEKLLDTEI or functional variants thereof.  
WO/2019/005685A1
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II: wherein each o...  
WO/2019/003104A1
The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an A...  
WO/2019/002875A1
The invention relates to improvements in drug delivery and to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (...  
WO/2018/236698A1
A pharmaceutically acceptable transdermal composition for the treatment of patients with musculoskeletal connective tissue fibrosis or a disorder including Dupuytren's Contracture, Peyronie's disease, Ledderhose disease, or Knuckle Pads,...  
WO/2018/234284A1
The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2018/232735A1
Provided is use of regulator in preparation of a medicament for regulating at least one of the following, wherein the regulator is used for activating or inhibiting Piezo: blood vessel development; blood pressure regulation; red blood ce...  
WO/2018/236186A1
The present invention relates to a pharmaceutical composition containing a sesquiterpene derivative or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of muscle diseases.  
WO/2018/235899A1
Provided is a method for culturing muscle stem cells while maintaining the undifferentiated properties of the cells. More specifically, muscle stem cells can be cultured while maintaining the undifferentiated properties of the cells by c...  
WO/2018/230535A1
The present invention provides a skeletal muscle injury repair accelerator which contains, as an active ingredient: at least one selected from among (1) a peptide having the amino acid sequence represented by SEQ ID NO: 1, (2) a peptide ...  
WO/2018/229629A1
A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne ...  
WO/2018/225673A1
Disclosed are: a method for manufacturing a therapeutic composition containing mammalian cells, said method comprising dispersing the mammalian cells in an aqueous glucose solution having a concentration of about 3-10% or Ringer's acetat...  
WO/2018/224636A1
The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regenerati...  
WO/2018/225065A1
Novel aminoglycosides, represented by Formulae (e.g., a compound of Formula A, B, I, I*, III or III*, including compounds represented by Formula Ia, I**, I*a, I*b, IIIa, III**, III*a and, III*b), as defined in the instant specification, ...  
WO/2018/221521A1
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives o...  
WO/2018/221543A1
The present invention provides: an I-type crystal of (E)-2-(7-trifluoromethyl chromane-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaph thalene-1-yl)acetamide having an excellent TRPV1 antagonistic activity; a medication and a medicat...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/221526A1
[Problem] To provide a high-calorie nutritional composition having good flavor and stable physical properties. [Solution] A nutritional composition comprises a protein source. The protein source of the nutritional composition includes wh...  
WO/2018/221654A1
The invention provides citrulline or a salt thereof and glutathione or a salt thereof for use in increasing a ratio of muscle mass to total body weight in a person in conjunction with a resistance workout program, as well as a method of ...  
WO/2018/216818A1
[Problem] To obtain a muscle quality improvement agent that is administered orally to a human or animal individual and that is able to cause qualitative change of muscle fibers of an individual administered to. [Solution] Provided is a m...  
WO/2018/213340A1
Provided are a recombinant acid α-glucosidase and pharmaceutical composition comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an in...  
WO/2018/211425A1
A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration ...  
WO/2018/213715A1
Provided herein are methods and compositions related to treating and/or preventing sleep disorders and for improving sleep health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comp...  
WO/2018/211510A1
Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.  
WO/2018/211498A1
Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are mor...  
WO/2018/207918A1
Provided is a method for easily and highly efficiently purifying and concentrating mesenchymal stem cells (MSC). More specifically, mesenchymal stem cells (MSC) can be easily and highly efficiently purified and concentrated by separating...  
WO/2018/207741A1
The purpose of the present invention is to provide drugs which are capable of promoting the biosynthesis of PGC-1α participating in energy production or inhibiting slow-to-fast muscle conversion caused by, for example, lack of exercise,...  
WO/2018/204617A8
The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration various routes, including subcutaneous (SC), for tr...  
WO/2018/204617A1
The present invention relates generally to stable liquid formulations comprising polypeptides with 10Fn3 domains which bind to myostatin and unit dosage forms thereof for administration various routes, including subcutaneous (SC), for tr...  
WO/2018/203559A1
Provided are: pharmaceutical compositions for polyglutamine diseases and the uses thereof; methods for prevention, amelioration, progress-suppression and/or treatment of polyglutamine diseases using such pharmaceutical compositions; and ...  
WO/2018/197708A1
The invention relates to 20-hydroxyecdysone and the derivatives thereof, for use in the treatment of genetic myopathies.  
WO/2018/197731A1
The invention concerns a method for preparing an extract from a preparation of approximately 90% pure 20-hydroxyecdysone that comprises the following steps: g) Hot dissolution of approximately 90% pure 20-hydroxyecdysone in methanol, fil...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/199109A1
Provided is a therapeutic agent, a preventive agent, or the like that is for diseases caused by accumulation of abnormal protein and that contains a compound represented by general formula (I) (in the formula, R1 and R2 each represent a ...  
WO/2018/200605A1
Provided herein are methods for treating levodopa-induced dyskinesia by administering to a subject (,S)-2-amino-3 -methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy- 1,3,4,6,7,11b-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-yl este...  
WO/2018/195046A1
The present disclosure provides a method for stimulating asymmetric division of at least some satellite stem cells in a patient suffering from a disease or disorder characterized by satellite cells having an inability, or a reduced abili...  
WO/2018/189208A1
The present invention concerns the use of antisense oligonucleotides (AON) capable of inhibiting expression of dynamin 2, advantageously human dynamin 2, for use in the treatment of Charcot-Marie-Tooth disease (CMT) and centronuclear myo...  
WO/2018/187493A1
Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregn...  
WO/2018/187209A1
In certain aspects, the disclosure provides compositions and methods for treating spinal muscular atrophy. For example, in some embodiments, the disclosure provides ALK4:ActRIIB antagonists that may be used to treat spinal muscular atrop...  
WO/2018/186480A1
The inventors of the present invention found that an HMGB1 peptide fragment having a specific amino acid sequence is effective at suppressing finger fusion and scarring of the digestive tract, and at prolonging survival in malnutrition- ...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/177244A1
An shRNA expression cassette, a polynucleotide sequence carrying the expression cassette, and an application thereof. The shRNA expression cassette contains, in order from 5' to 3', a DNA sequence expressing the shRNA and a filler sequen...  
WO/2018/178029A1
The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that SIRT3 is decreased with age in human striated muscles which are post-mitotic cells. More pa...  
WO/2018/178237A1
The invention relates to a method for treating mitochondrial genetic diseases. The inventors have worked with primary fibroblasts from patients and control individuals and collected protein lysates for western blotting. Importantly, they...  
WO/2018/181345A1
Provided is a compound which has an Nrf2-activating activity and is expected to be useful as a prophylactic or therapeutic agent for diseases associated with oxidative stress, particularly hepatitis (e.g., non-alcoholic steatohepatitis (...  

Matches 1 - 50 out of 24,254